Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen total Product Sales — Rest of World (ROW) volume growth YoY (%) (%)
Form 10-Q / 10-K Item 2/7 MD&A Product Sales Overview
Latest, FY2025
14.0%
Period ended Dec 31, 2025
Change on a year earlier
-3.0 pts
17.0% in FY2024
History
2 years
Since FY2024
Sources
2
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total Product Sales — Rest of World (ROW) volume growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 14.0% | -3.0 pts | Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 17.0% | – | Form 10-K (amgn-20241231.htm, filed 2025-02-14) ↗ |
Cite this data
StockData. (2026). Amgen Total Product Sales — Rest of World (ROW) volume growth YoY (%) (%), annual FY2024–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_total_row_vol
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.